ERIE — Erie Indemnity Company

As of 2026-09-13 the tape and the sell side disagree, and the tape is winning. ERIE fell about 6% immediately after its July 30, 2026 Q2 beat, and as of this date it sits -3.07% over one week, -5.09% over one month, and -0.76% over six months, with price below all three key moving averages even though the 3-month return is still +8.1%. Wall Street consensus remains a cautious 'Moderate Buy,' but the market is focused on the deceleration story: Exchange premium growth has normalized after 2025's >10% cumulative rate increases, policy retention has slipped into the high-80s from a historic low-90s, and because Indemnity's fee is a percentage of Exchange written premium, that taper mechanically caps top-line growth. The announced retirement of CFO Julie Pelkowski at end-2026 adds mild governance uncertainty on top. Nobody is panicking - the 2.24% dividend and 0.305 beta keep it defensive - but there is no growth enthusiasm either.

Revenue growth has decelerated steadily and unambiguously over the three-year window: +16.4% YoY in Q3 2024, +13.0% in Q4 2024, +12.3% in Q1 2025, +7.0% in Q2 2025, +6.8% in Q3 2025, +2.9% in Q4 2025, +2.3% in Q1 2026, and +2.8% in Q2 2026 ($1,089.8M vs $1,059.7M). That is a fall from low-double-digit to low-single-digit growth in six quarters - a structural deceleration tied to premium rate normalization, not a one-quarter blip. Margins, by contrast, are holding: operating margin was 18.73% in Q2 2026 versus 18.84% in Q2 2025, 19.70% in Q3 2025, and 18.11% in Q4 2024, so roughly a flat 17-19% band with Q1 seasonally weakest (16.40% in Q1 2026, 15.30% in Q1 2025). The real anomaly is Q4 2025: $157.7M of operating income converted to only $63.4M of net income and $1.20 of diluted EPS, a ~$94M gap versus the ~$24-27M gap in normal quarters. That is a large non-operating charge (tax item, investment loss, or similar) that is NOT explained in the data provided, and it is the single biggest distortion in the reported trailing numbers. Excluding it, quarterly EPS has run a stable $2.65-$3.47 for two years, and Q2 2026 net income of $180.3M rose 3.2% YoY. Free cash flow is lumpy but healthy: TTM FCF through 2026-06-30 is $553.1M versus $564.0M for the prior TTM (-1.9%), while calendar 2025 FCF of $571.0M was up 17.4% over 2024's $486.4M. Bottom line: decelerating revenue, stable margins, stable-to-slightly-growing earnings, one noisy quarter.

Fair, tilting modestly cheap on absolute terms but not the bargain the historical comparison implies. As of 2026-09-13, at $245.03, ERIE trades at 19.78x trailing EPS of $12.492 and about 19.3x the $12.68 next-FY consensus EPS - a steep discount to its own 5-year average P/E of 31.94x, and P/S of 2.747x versus a 5-year average of 4.09x. The deterministic valuation overlay rightly flags this as 'Cheap vs. its own history' (score 94.3). But that historical multiple was earned during a period of 12-16% revenue growth; with growth now at ~2.8%, a persistent de-rating is deserved rather than anomalous, and the PEG ratio of -2.6 is meaningless because it is distorted by the anomalous Q4 2025 print. On quality, the case is strong: 24.5% ROE, 23.2% ROIC, 0.026 debt/equity (zero long-term debt on the balance sheet), a 2.24% dividend yield at only ~46% payout, and a 0.305 beta. Roughly 19-20x forward earnings for a debt-free, 24%-ROE, low-beta compounder growing 3-5% is a defensible price - neither a steal nor a stretch.

Read the trailing multiple carefully, because it is polluted. The 19.78x TTM P/E is calculated off $12.492 of TTM EPS that includes a Q4 2025 in which $157.7M of operating income became just $63.4M of net income ($1.20 EPS) - roughly a $3.00-3.45 earnings quarter reported as $1.20. Normalize that one quarter and trailing EPS is closer to $14.0 and the trailing multiple nearer 17.5x. Meanwhile, the consensus next-FY EPS of $12.68 already embeds a normalized Q4 2026 (H1 2026 actual EPS is $6.31, so $12.68 requires about $6.37 in H2 versus $4.67 in H2 2025). So the market is paying about 19x for clean, ex-anomaly earnings and is pricing in roughly 3-5% EPS growth in perpetuity - it is not pricing a growth recovery, and it is not pricing a collapse. The re-rating trigger is a Q3 2026 report (due Oct 29, 2026) showing fee revenue growth holding at or above ~4.5% with retention stabilizing and no repeat charge; that would push the clean-forward multiple math toward the high-teens and make the stock look obviously cheap. The de-rating trigger is any evidence that policy counts are falling rather than just growing more slowly.

Range-bound with a mild downward tilt. As of 2026-09-13, RSI(14) was 44.81 - neutral, neither oversold nor overbought, so no mean-reversion signal. Price was -4.15% below its 20-day SMA (implied near $255.6), -0.65% below its 50-day (near $246.6), and -3.27% below its 200-day (near $253.3), meaning the stock has slipped back under all three averages after a rally that produced a +8.1% three-month return. The one-month return of -5.09% and one-week return of -3.07% show the pullback is still in motion rather than exhausted. ERIE is sitting in the lower-middle of a wide 52-week range of $204.63-$341.71, so there is a long way down to major support at the $204-210 area. Entry-timing implication: there is no urgency and no technical edge here. A patient buyer should either wait for RSI below ~35 near $210-215, or wait for a reclaim of the 200-day (~$253) to confirm the consolidation is resolving upward. Buying at $245 with RSI at 44.8 is buying in the middle of a range with no momentum.

• P&C premium rate normalization: after cumulative 2025 rate increases averaging over 10% at the Exchange, written premium growth has decelerated sharply - and Indemnity's management fee is a direct percentage of that premium, so its revenue growth mechanically follows the Exchange's pricing cycle with a lag.
• Consumer price sensitivity and shopping behavior in auto/home insurance: Exchange policy retention has fallen into the high-80s from a historical low-90s, a demand-side headwind that could turn fee revenue growth negative if policy counts actually decline rather than just grow more slowly.
• Interest rates and investment income: pre-tax investment income rose to $22.6M in Q2 2026 from $19.6M a year earlier, so a higher-for-longer rate environment is a modest tailwind - but it is a small slice of earnings next to fee revenue, and the same rates pressure the multiple on a 0.305-beta, 2.24%-yielding bond-proxy equity.
• Claim severity and social inflation: rising loss costs force the Exchange to file more rate increases, which supports Indemnity's fee revenue but simultaneously worsens retention - the two effects partly cancel, making the net outcome on fee growth uncertain.
• Defensive/low-volatility sector rotation: with beta of 0.305 and a growing dividend, ERIE trades as a defensive holding whose relative performance depends heavily on whether capital is rotating into or out of low-volatility financials, independent of the company's own fundamentals.

• Q3 2026 earnings on Thursday, October 29, 2026 (after market close): the key reads are whether fee revenue growth holds near the ~4.5% pace, whether policy retention stabilizes in the high-80s or deteriorates further, and whether another large Q4-style below-the-line charge appears.
• The Q4 2025 charge rolling out of the trailing comparison at year-end 2026: this will mechanically lift reported TTM EPS and lower the trailing P/E without any change in underlying economics, potentially re-framing the stock as cheaper than it screens today.
• CFO succession: an announcement naming a successor to Julie Pelkowski (retiring end-2026) would remove a minor overhang and give investors a read on capital-allocation continuity.
• Dividend compounding: the board raised the quarterly dividend 7% to $1.4625 (payable October 20, 2026), and at roughly a 46% payout ratio against ~24.5% ROE there is substantial room for continued high-single-digit or low-double-digit dividend growth.
• Any reset of the management fee rate or new terms under the agreement between Indemnity and the Erie Insurance Exchange - this is the single largest earnings lever and is entirely outside what the trailing data can show; a favorable reset would be a genuine positive surprise.

• Retention deterioration becomes a policy-count problem: fee revenue is a percentage of Exchange written premium, so if retention in the high-80s translates into an outright decline in policies in force, revenue growth does not just slow - it goes negative, and the entire deceleration thesis gets worse than modeled.
• Extreme counterparty concentration: essentially all of Indemnity's revenue derives from a single entity, the Erie Insurance Exchange, under a contract whose fee rate is determined through that relationship - the company has no independent pricing power and no diversified customer base.
• The growth deceleration may be structural rather than cyclical: revenue YoY fell from +16.4% (Q3 2024) to +2.8% (Q2 2026) as the rate cycle normalized, and if that is the new steady state, the 31.94x 5-year average P/E is never coming back - meaning today's 'cheap vs. history' signal is a value trap rather than an opportunity.
• The unexplained ~$94M gap between Q4 2025 operating income ($157.7M) and net income ($63.4M) has not been characterized in the data available; if whatever caused it is recurring in nature rather than a one-off, TTM earnings quality is materially worse than the headline $12.492 suggests.
• Multiple/rate sensitivity: as a 0.305-beta, 2.24%-yielding low-volatility name, ERIE's valuation rests partly on its bond-proxy appeal - a sustained rise in long rates or a rotation out of defensives could compress the multiple regardless of how the fee business performs.
• Key-personnel transition risk around the CFO seat at a company where financial reporting and the Exchange relationship are closely intertwined, with the handover landing right at the year-end 2026 reporting cycle.

Erie Indemnity is a genuinely high-quality, debt-free, 24.5%-ROE fee manager with zero underwriting risk, a 2.24% dividend at half payout, and a 0.305 beta - but at $245.03 on 2026-09-13 it is roughly fairly valued, not a bargain. The 'cheap vs. its own history' signal (19.8x trailing P/E against a 31.94x 5-year average) is real but substantially deserved: revenue growth has collapsed from ~16% to ~2.8% YoY, retention has slipped from the low-90s to the high-80s, and 100% of revenue depends on one counterparty whose premium volume Indemnity does not control. I would want either a pullback toward the $205-215 support zone or a Q3/Q4 2026 print showing retention and fee growth stabilizing before treating this as an attractive entry. For an income-oriented investor who wants a low-volatility compounder and can tolerate low-single-digit growth, it is a reasonable hold; for anyone buying for upside, the catalysts are not there yet.

I blended two methods, weighted ~65% to a multiple-based approach and ~35% to a DCF. The multiple approach applies a 20.5x justified forward P/E - a ~36% discount to the 5-year average of 31.94x, justified by the shift from double-digit to low-single-digit revenue growth, but still above what a simple Gordon model at an 8-9% cost of equity would produce, reflecting the 24.5% ROE, zero long-term debt, and 0.305 beta - to the $12.68 next-FY consensus EPS, giving ~$260. The DCF capitalizes TTM free cash flow of $553.1M at 5.5% growth, a 9% discount rate, and 2.5% terminal growth across 46.19M shares, giving ~$237. Weighting these gives roughly $252, implying the stock is close to, and only modestly below, fair value as of 2026-09-13.